What changed
In 2026 about 112,000 Americans will hear a melanoma diagnosis, up from prior decades, because the disease has been getting more common. Melanoma will kill more than 8,500 Americans this year, which means it remains one of the deadliest skin cancers. For most patients, surgery takes the tumor out and then a wait begins. That wait is the whole problem: melanoma most often returns within the first two years, and when it returns it has usually spread rather than stayed put. For patients whose melanoma reached stage IIB or beyond, meaning it grew deep or spread, the drug given during that wait is Keytruda. Merck and Moderna said on August 19, 2026 that adding an experimental mRNA shot to Keytruda kept melanoma away longer than Keytruda alone, which means the standard was beaten for the first time. Moderna says the shot is made for one person: doctors send a piece of the tumor, its mutations are read, and a dose is built for that patient. It is made from mRNA, the same technology as the COVID vaccine that made Moderna a household name. The August release shows 1,137 patients randomized two to one, which means about two in three received the shot rather than Keytruda alone.
How far Moderna stock rose in Wednesday morning trading, to about $161 a share, on a release that published no efficacy figure.
- January 2The low
Moderna shares hit $29.81, their weakest level of the year.
- August 19Topline result
Both endpoints met. No effect size published.
- NextMedical meeting
The companies say the full data will be presented.
- ThenRegulators
The companies say they will engage on filing submissions.
An approaching patent expiry is why Merck reached for Moderna's shot, and the pair beat Merck's own drug by an amount neither company has published.
- An approaching patent expiryon Keytruda, Merck's best-selling cancer treatment
- is why Merck reached forIntismeranModerna's shot, built from one patient's own tumourthreatensKeytrudathe standard given after melanoma surgery
- and the trial paired themThe two given togetherthe arm of the trial that won
- which beatBeat Keytruda aloneby an amount neither company has published
So the pairing that protects Merck's franchise is also the one your oncologist cannot yet weigh — the size of the benefit is the part that was not released.
Spoke for Moderna in the release announcing this result. Neither company has published how much better the combination was in this trial. Merck's research president says the data will be presented at an international medical meeting.
These Phase 3 findings represent a pivotal moment for the field of cancer research. For many years, the idea of creating an mRNA treatment designed specifically for an individual patient's cancer was aspirational. We are now helping turn that vision into a reality. Together with Merck, we have started to demonstrate the transformative potential of this technology to address critical unmet needs in the adjuvant melanoma setting. We are deeply grateful to the patients, investigators and study teams whose contributions make this progress possible.Photograph: Moderna
Why it matters
What the release did not say is how much better. No percentage for this trial, no survival figure, nothing an oncologist could weigh against the treatment they already give. The same partners printed exact numbers for their earlier study. This time nobody outside the trial can tell whether the gap is wide or narrow. Underneath that gap runs a business clock most readers never see. Keytruda is Merck's best-selling cancer treatment and its patent protection is running out, so a combination that keeps Keytruda at the center of a new standard protects the franchise that matters most. Forbes reports that Leerink analyst Mani Foroohar called this readout a make-or-break event for Moderna's stock in June 2026, which means the market had more riding on it than on a routine result. That suggests the stakes were commercial as well as clinical. The market agreed before the size was public. In August 2026 Moderna stock more than doubled in one session, which means four insiders picked up a combined $4.6 billion of paper wealth, summed from four Forbes estimates. If you hold the stock, you were paid for a direction and not for a size.
What to watch
Three things stand between this result and a patient. Two are paperwork: there is no regulatory submission yet, and there is no price. The third is science, because the trial cleared its main goal at a planned early look called an interim analysis, and it is still running to see whether people live longer. Beyond those three sits a political clock, and it touches mRNA work broadly rather than this trial. Forbes reports that Robert F. Kennedy Jr., the federal health secretary, is a critic of mRNA COVID vaccines. The 2026 Forbes account says he would cancel nearly $500 million of funding for them, which would cost mRNA work public money rather than private. That money is tied to vaccines, not to this cancer therapy, and no source connects the two. Back inside the clinic, if someone in your family has had a melanoma removed, the useful question for their oncologist is not whether to switch now, because nothing is approved and nothing is priced. It is what the full data shows for overall survival, the measure of whether people lived longer rather than simply relapsed later. Two groups are working from different information. Investors traded on a direction that is already public. Patients are waiting for numbers that are not. If overall survival lands the same way, this could become the treatment given after melanoma surgery. It is still unclear how large the benefit is.
Reader comments
Not signed in yet — hit Post and we'll finish it together